Physician

Bei Fang Liu, MD, PHD

According to 2025 Medicare claims, Bei Liu, MD, PHD (NPI: 1508887829) practices hematology/oncology in the Saginaw, MI market, with the plurality of this provider's patient population coming from Saginaw, MI. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY ASSOCIATES OF SAGINAW VALLEY PC (NPI: 1366472169; TIN: 383553403) and primary practice location at 48604-9533. Liu is affiliated with the POM ACO (ACO ID: A1297), McLaren High Performance Network, LLC (ACO ID: A3317), Mosaic ACO (ACO ID: A5033), Aledade 155 National MSSP (ACO ID: A5358), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Liu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 481 traditional Medicare patients, billed 103,418 HCPCS/CPT codes, and received $2,283,268 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,331 prescription claims across 304 beneficiaries totaling $6,404,190 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 33 claims. Open Payments data shows 92 records totaling $2,159. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,621,974 to $6,404,190. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	735	160,942	$1,832,102
2016	1,006	215,780	$2,472,847
2017	935	197,353	$2,459,046
2018	779	140,124	$1,779,891
2019	753	125,920	$1,940,247
2020	679	101,802	$2,390,931
2021	625	104,972	$2,115,507
2022	620	104,928	$1,868,500
2023	545	88,238	$1,594,470
2024	481	103,418	$2,283,268

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	233	1,254	$1,621,974
2016	353	1,510	$2,333,638
2017	343	1,568	$3,019,542
2018	339	1,568	$3,524,812
2019	294	1,383	$3,782,499
2020	319	1,490	$4,525,536
2021	294	1,167	$3,884,493
2022	276	1,112	$4,226,937
2023	321	1,403	$6,536,932
2024	304	1,331	$6,404,190

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	25	240	$68,133
2016	N/R	40	$597
2017	N/R	N/R	N/R
2018	N/R	14	$830
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	52	$2,600
2023	N/R	41	$8,172
2024	N/R	33	$1,233

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	281	510	$93
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	75	223	$63
80053	Blood test, comprehensive group of blood chemicals	135	415	$10
36415	Insertion of needle into vein for collection of blood sample	133	441	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	148	703	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	73	2,060	$1,020,708
Revlimid	Lenalidomide	58	1,379	$905,539
Cabometyx	Cabozantinib S-Malate	23	690	$607,586
Lenalidomide	Lenalidomide	44	1,113	$598,409
Sprycel	Dasatinib	30	900	$536,337

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$1,070
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	92	$2,159	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bei Fang Liu, MD, PHD?

Tedicare shows public-source Medicare data for Bei Fang Liu, MD, PHD (NPI 1508887829), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bei Fang Liu, MD, PHD have ACO affiliation data?

Bei Fang Liu, MD, PHD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297), McLaren High Performance Network, LLC (MSSP, ACO ID A3317), Mosaic ACO (MSSP, ACO ID A5033), Aledade 155 National MSSP (MSSP, ACO ID A5358), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Bei Fang Liu, MD, PHD?

Bei Fang Liu, MD, PHD is linked to ONCOLOGY HEMATOLOGY ASSOCIATES OF SAGINAW VALLEY PC (billing NPI 1366472169) in the available physician profile data.

Does Bei Fang Liu, MD, PHD have Open Payments data?

Bei Fang Liu, MD, PHD has 92 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.